Search Results - Moy, B.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 tria... by Chan, Arlene, Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S., Mansi, J., Barrios, C., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Zotano, A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M.

    Published 2016
    Get full text
  2. 2
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J., Barrios, C., Gnant, M., Tomaševic, Z., Denduluri, N., Šeparovic, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S., Jakobsen, E., Ciceniene, A., Inoue, K., Overkamp, F., Heijns, J., Armstrong, A., Link, J., Joy, A., Bryce, R., Wong, A., Moran, S., Yao, B., Xu, F., Auerbach, A., Buyse, M., Chan, Arlene, ExteNET Study Group

    Published 2017
    Get full text

Search Tools: